Fennec Pharmaceuticals Stock Net Income
| FENC Stock | USD 7.85 0.14 1.82% |
As of the 28th of January, Fennec Pharmaceuticals shows the Variance of 8.18, standard deviation of 2.86, and Mean Deviation of 2.08. Fennec Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fennec Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 6.7138 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -392.4 K | -412 K | |
| Net Loss | -21.3 M | -20.3 M | |
| Net Loss | -392.4 K | -412 K | |
| Net Loss | (0.01) | (0.02) | |
| Net Income Per E B T | 5.53 | 5.80 |
Fennec | Net Income | Build AI portfolio with Fennec Stock |
Latest Fennec Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Fennec Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fennec Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Fennec Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fennec Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fennec Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (436 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Fennec Net Income Regression Statistics
| Arithmetic Mean | (6,506,499) | |
| Coefficient Of Variation | (124.54) | |
| Mean Deviation | 6,820,031 | |
| Median | (2,789,000) | |
| Standard Deviation | 8,103,505 | |
| Sample Variance | 65.7T | |
| Range | 27.5M | |
| R-Value | (0.39) | |
| Mean Square Error | 59.4T | |
| R-Squared | 0.15 | |
| Significance | 0.12 | |
| Slope | (625,486) | |
| Total Sum of Squares | 1050.7T |
Fennec Net Income History
Other Fundumenentals of Fennec Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Fennec Pharmaceuticals Net Income component correlations
Fennec Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Fennec Pharmaceuticals is extremely important. It helps to project a fair market value of Fennec Stock properly, considering its historical fundamentals such as Net Income. Since Fennec Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fennec Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fennec Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Fennec Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fennec Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fennec Pharmaceuticals.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Fennec Pharmaceuticals on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Fennec Pharmaceuticals or generate 0.0% return on investment in Fennec Pharmaceuticals over 90 days. Fennec Pharmaceuticals is related to or competes with Aardvark Therapeutics, Cartesian Therapeutics, Prelude Therapeutics, Caribou Biosciences, Avalo Therapeutics, Enanta Pharmaceuticals, and Black Diamond. Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company More
Fennec Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fennec Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fennec Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 17.84 | |||
| Value At Risk | (4.27) | |||
| Potential Upside | 4.19 |
Fennec Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fennec Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fennec Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Fennec Pharmaceuticals historical prices to predict the future Fennec Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.40) | |||
| Treynor Ratio | (0.42) |
Fennec Pharmaceuticals January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.41) | |||
| Mean Deviation | 2.08 | |||
| Coefficient Of Variation | (2,397) | |||
| Standard Deviation | 2.86 | |||
| Variance | 8.18 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.40) | |||
| Treynor Ratio | (0.42) | |||
| Maximum Drawdown | 17.84 | |||
| Value At Risk | (4.27) | |||
| Potential Upside | 4.19 | |||
| Skewness | 0.8932 | |||
| Kurtosis | 3.05 |
Fennec Pharmaceuticals Backtested Returns
Fennec Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0195, which denotes the company had a -0.0195 % return per unit of risk over the last 3 months. Fennec Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Fennec Pharmaceuticals' Mean Deviation of 2.08, variance of 8.18, and Standard Deviation of 2.86 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, Fennec Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Fennec Pharmaceuticals is expected to be smaller as well. At this point, Fennec Pharmaceuticals has a negative expected return of -0.0572%. Please make sure to confirm Fennec Pharmaceuticals' maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Fennec Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.13 |
Insignificant reverse predictability
Fennec Pharmaceuticals has insignificant reverse predictability. Overlapping area represents the amount of predictability between Fennec Pharmaceuticals time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fennec Pharmaceuticals price movement. The serial correlation of -0.13 indicates that less than 13.0% of current Fennec Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.13 | |
| Spearman Rank Test | -0.18 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Fennec Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Fennec Pharmaceuticals reported net income of (436,000). This is 100.13% lower than that of the Biotechnology sector and 100.62% lower than that of the Health Care industry. The net income for all United States stocks is 100.08% higher than that of the company.
Fennec Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fennec Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fennec Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Fennec Pharmaceuticals by comparing valuation metrics of similar companies.Fennec Pharmaceuticals is currently under evaluation in net income category among its peers.
Fennec Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fennec Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fennec Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Fennec Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Fennec Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Fennec Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fennec Pharmaceuticals' value.| Shares | Gendell Jeffrey L | 2025-06-30 | 139.7 K | Northern Trust Corp | 2025-06-30 | 131.5 K | The Informed Momentum Company (formerly Eam Investors) | 2025-06-30 | 78.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 61.3 K | Bank Of New York Mellon Corp | 2025-06-30 | 51.8 K | Hartford Financial Management Inc. | 2025-06-30 | 50.6 K | Jane Street Group Llc | 2025-06-30 | 50 K | Susquehanna International Group, Llp | 2025-06-30 | 46.9 K | Citadel Advisors Llc | 2025-06-30 | 46.8 K | Southpoint Capital Advisors Lp | 2025-06-30 | 4.1 M | Solas Capital Management Llc | 2025-06-30 | 2.2 M |
Fennec Fundamentals
| Return On Equity | -10.06 | ||||
| Return On Asset | -0.0539 | ||||
| Profit Margin | (0.18) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 260.43 M | ||||
| Shares Outstanding | 34.15 M | ||||
| Shares Owned By Insiders | 13.37 % | ||||
| Shares Owned By Institutions | 43.89 % | ||||
| Number Of Shares Shorted | 777.87 K | ||||
| Price To Earning | (3.82) X | ||||
| Price To Book | 57.93 X | ||||
| Price To Sales | 6.91 X | ||||
| Revenue | 47.54 M | ||||
| Gross Profit | 36.12 M | ||||
| EBITDA | 4.8 M | ||||
| Net Income | (436 K) | ||||
| Cash And Equivalents | 14.91 M | ||||
| Cash Per Share | 0.57 X | ||||
| Total Debt | 19.34 M | ||||
| Debt To Equity | 0.58 % | ||||
| Current Ratio | 5.12 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | 26.98 M | ||||
| Short Ratio | 4.26 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 15.17 | ||||
| Number Of Employees | 32 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 268.1 M | ||||
| Total Asset | 44.95 M | ||||
| Retained Earnings | (219.68 M) | ||||
| Working Capital | 37.2 M | ||||
| Current Asset | 7.88 M | ||||
| Current Liabilities | 1.97 M | ||||
| Net Asset | 44.95 M |
About Fennec Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fennec Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fennec Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fennec Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Fennec Pharmaceuticals Piotroski F Score and Fennec Pharmaceuticals Altman Z Score analysis. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.787 | Return On Assets | Return On Equity |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.